通过ReX平台优化CFTR调节器治疗的治疗管理,以治疗囊性纤维化
Karin Yaacoby-Bianu1,2, Malena Cohen-Cymberknoh3, David Shoseyov3
1Pediatric Pulmonology Unit and CF Center, Carmel Medical Center, Haifa, Israel.
Frontiers in pediatrics
|January 5, 2024
概括
ReX平台使用CFTR调节器改善了囊性纤维化患者的药物坚持和临床结果. 这种安全和用户友好的系统可以提高治疗管理,并可能降低医疗保健成本.
科学领域:
- 医疗技术 医疗技术 医学技术
- 患者参与 患者参与
- 慢性疾病管理 慢性疾病管理
背景情况:
- 囊性纤维化 (CF) 是一种复杂的多系统性疾病,需要每天进行密集治疗.
- 低于最佳的CF治疗效果显著影响临床和经济负担.
- 囊性纤维化跨膜导电调节器 (CFTRm) 是一种高成本,有效的CF药物.
研究的目的:
- 评估ReX平台的安全性,可用性和有效性,用于CFTR调节器在CF (pwCF) 患者的药物管理.
主要方法:
- 一项前性,多中心的开放性研究,涉及pwCF (年龄大于12岁) 处方CFTRm (ETI或TI).
- ReX平台用于药物发行,提醒和遵守数据收集.
- 研究持续时间为12-24个月,包括临床访问,包括体检,BMI,肺功能测试和用户体验问卷.
主要成果:
- 对CFTRm的平均坚持率为97.5% (第一年) 和94% (第二年),超过报告的~80%的坚持率.
- 没有报告与ReX平台相关的不良事件;患者认为它是有价值的和用户友好的.
- 观察到的显著改善:平均FEV1%从74.4%增加到80.8% (p=0.004),BMI百分位数从53.5增加到59.0 (p<0.001).
结论:
- 雷克斯平台是一个安全,用户友好和有效的工具,用于管理pwCF中的CFTRm.
- 该平台展示了改善治疗坚持和临床结果的潜力.
- 需要进一步的大规模,长期的研究来证实临床益处和成本效益.
更多相关视频
08:00Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Published on: April 11, 2018
10.7K
09:59Functional Reconstitution and Channel Activity Measurements of Purified Wildtype and Mutant CFTR Protein
Published on: March 9, 2015
12.2K
相关概念视频
Cystic Fibrosis: Management
166
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
166
Cystic Fibrosis: Pathogenesis
244
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
244
COPD: Management Using Bronchodilators and Corticosteroids
208
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
208
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142
